Axsome Therapeutic's drug, Auvelity was approved for depression in 2022, and completed it's first full year in 2023. The chart below is quarterly prescription data derived from a couple different sources, Bloomberg and IQVIA. The numbers are climbing from quarter to quarter, which is positive. The first quarter of 2025 numbers have not been released yet, so a rough estimate has been created. See chart below. Axsome reports first quarter results on May 5th.
Previous gold post's are here Gold Showing Strength and here Gold Revaluation. The tariffs bought a new high to gold, along with wealth preservation amidst fiat currency devaluation, and geo political uncertainty. It would seem all is in favor of owning physical gold, or at the very least, have assets invested in gold funds. Gold hit $3,184 per ounce today with no overhead resistance to higher prices. If you have a chance to read Fiat Money Inflation in France, it would be an eye opener regarding fiat currency and similarities, historically to today. Chart of gold. Thank you for reading.
Axsome released phase 3 clinical data from the (FOCUS) study with drug Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD), with results being statistically significant, rated under the AISRS (primary endpoint) versus placebo with 150mg dose.
FOCUS Phase 3 Results:
